Innovent Biologics' Mazdutide Phase 3 Trial In Obesity Achieves Primary & Key Secondary Endpoints

Innovent Biologics said its Phase 3 GLORY-2 trial of mazdutide 9 mg in Chinese adults with obesity met the primary endpoint and all key secondary endpoints and that it will file a new drug application with China’s CDE/NMPA in the near term. At Week 60 the mazdutide 9 mg group saw a mean weight reduction of 18.55% versus 3.02% for placebo, with 44.0% achieving ≥20% weight loss (placebo 2.6%); in participants without type 2 diabetes mean weight loss was 20.08% with 48.7% achieving ≥20% (placebo 3.1%, p<0.0001). The drug also produced statistically superior improvements in waist circumference, systolic blood pressure, triglycerides, non‑HDL and LDL cholesterol, serum uric acid and showed a −71.9% mean change in liver fat by MRI‑PDFF in a high‑fat subset, with generally favorable tolerability and no new safety signals (treatment discontinuation for AEs 2.9% vs 0% for placebo).

Analysis

Innovent Biologics reported that the Phase 3 GLORY-2 trial of mazdutide 9 mg, a first-in-class dual glucagon/GLP-1 receptor agonist, met the trial's primary endpoint and all key secondary endpoints and that the company plans to file an NDA with China’s CDE/NMPA in the near term. The primary efficacy signal at Week 60 showed a mean weight reduction of 18.55% for mazdutide versus 3.02% for placebo, with 44.0% of treated participants achieving ≥20% weight loss versus 2.6% on placebo.

In the non–type 2 diabetes subgroup the drug produced a mean 20.08% weight reduction with 48.7% achieving ≥20% (placebo 3.1%, P<0.0001), and the study showed statistically superior improvements in waist circumference, systolic blood pressure, triglycerides, non‑HDL and LDL cholesterol, and serum uric acid. A MRI‑PDFF subset recorded a −71.9% mean change in liver fat for mazdutide versus +5.1% for placebo, suggesting materially different effects on hepatic fat content.

Safety readouts were described as favorable with no new signals, most gastrointestinal events coded mild–moderate and transient, and treatment discontinuation for adverse events of 2.9% versus 0% for placebo. These data materially strengthen Innovent’s regulatory dossier in China and imply potential broader cardiometabolic and hepatic benefits, but the NDA review timeline, final labeling, reimbursement decisions and any post‑marketing safety findings remain key near‑term risks; sentiment and market‑impact signals provided are strongly positive but not definitive for approval or commercial uptake.

Key Decisions for Investors

• Consider initiating or modestly increasing exposure to Innovent Biologics to capture upside from a near‑term NDA filing and robust Phase 3 efficacy results, sizing positions to reflect regulatory and execution risk
• Monitor CDE/NMPA filing date, review milestones, final labeling language and reimbursement signals as primary catalysts, and track safety follow‑up given the 2.9% discontinuation rate for adverse events
• Employ position hedging or defined exits to protect against regulatory delay or adverse post‑market events, and watch secondary endpoint readouts—especially liver fat reductions—as potential sources of additional commercial value